| Literature DB >> 31345630 |
Sabrina Chiloiro1, Ettore Domenico Capoluongo2, Tommaso Tartaglione3, Antonella Giampietro1, Antonio Bianchi1, Andrea Giustina4, Alfredo Pontecorvi1, Laura De Marinis5.
Abstract
Hypophysitis is a rare and potentially life-threatening disease, characterized by an elevated risk of complications, such as occurrence of acute central hypoadrenalism, persistent hypopituitarism, or extension of the inflammatory process to the neighboring neurological structures. In recent years, a large number of patients have been described as being affected by hypophysitis, due to the increased administration of immuno-chemotherapies. At the present time, the heterogeneous nature of hypophysitis diagnostic criteria and of the treatment protocols makes the management of affected patients difficult. We review the current data and evidence on primary and secondary hypophysitis, in order to suggest a diagnostic and therapeutic protocol that should be focused on a multidisciplinary approach, for reaching a prompt diagnosis and an appropriate and safe treatment.Entities:
Keywords: autoimmune; diabetes insipidus; hypopituitarism; immunotherapy; ipilimumab; pituitary
Year: 2019 PMID: 31345630 DOI: 10.1016/j.tem.2019.06.004
Source DB: PubMed Journal: Trends Endocrinol Metab ISSN: 1043-2760 Impact factor: 12.015